Entrada Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Multiple clinical readouts are expected in 2026 for DMD and DM1, with a focus on best-in-class dystrophin production and a robust cash runway into Q3 2027. Expansion into ocular diseases and a strong Vertex partnership support pipeline growth and regulatory progress.
-
Multiple clinical milestones are expected in 2024 for DMD and DM1 programs, with Q2 data anticipated to show strong safety and double-digit dystrophin levels. The EEV platform supports rapid expansion across exons, and regulatory discussions may enable higher dosing in the U.S.
-
Multiple clinical programs in DMD and DM1 are advancing, with key data readouts expected in 2026. Expansion into ocular diseases and a robust financial position support continued growth and pipeline diversification. Entrada's EEV platform offers strong differentiation and de-risking for future programs.
Fiscal Year 2025
-
EEV technology enables efficient, flexible delivery for DMD and DM1, with clinical trials for exons 44 and 45 underway and data expected in 2026. Strong regulatory engagement, low manufacturing costs, and a major DM1 partnership with Vertex position the platform for broad impact and expansion.
-
Entrada's EEV platform enables efficient intracellular delivery, showing strong preclinical and early clinical results in DMD, with robust safety and PK profiles. Clinical trials are advancing globally, focusing on both pediatric and underserved adult populations, while strategic partnerships and pipeline expansion continue to drive growth.
-
Four clinical programs are advancing toward activation by end of 2025, with robust progress in DMD and DM1, strong early safety and efficacy data, and a cash runway into Q2 2027. Platform expansion and new data in ocular and gene editing are expected later this year.
-
The EEV platform enables efficient delivery of therapeutics for DMD and DM1, with four exon skipping candidates advancing in the clinic and a strong partnership with Vertex for DM1. The company maintains a robust pipeline, including ocular programs, and has operational runway into 2027.
-
Entering 2025 with strong momentum, four phase I MAD studies in DMD and DM1 are planned, supported by robust clinical and preclinical data. The EEV platform enables broad pipeline expansion, and a cash runway into Q2 2027 supports continued growth and patient-focused development.
Fiscal Year 2024
-
Phase 2 trials for three DMD programs are on track to start globally next year, supported by strong safety and PK data from the EEV platform. The company expects a cash runway into 2027 and is open to strategic partnerships that align with its platform goals.
-
Significant progress was reported in advancing DMD and DM1 programs, with strong preclinical and clinical data supporting the EEV platform's efficacy and safety. Financial strength and strategic partnerships, notably with Vertex, position the company for continued pipeline expansion and global clinical development.
-
The EEV platform enables targeting of previously inaccessible intracellular targets, with strong preclinical and early clinical data in DMD and DM1. Key October data will focus on safety and muscle concentration, supporting global phase 2 plans. The pipeline is expanding into new modalities, and financials are strong with a cash runway through Q2 2026.